MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/infdis/jis753

Медицинская библиотека · The Journal of infectious diseases · 2012

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg Richard N, Overton Edgar Turner, Haas David W, Frank Ian, Goldman Mitchell, von Krempelhuber Alfred, Virgin Garth, Bädeker Nicole, Vollmar Jens, Chaplin Paul

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Human immunodeficiency virus (HIV)-infected persons are at higher risk for serious complications associated with traditional smallpox vaccines. Alternative smallpox vaccines with an improved safety profile would address this unmet medical need.

METHODS

The safety and immunogenicity of modified vaccinia Ankara (MVA) was assessed in 91 HIV-infected adult subjects (CD4(+) T-cell counts, ≥350 cells/mm(3)) and 60 uninfected volunteers. The primary objectives were to evaluate the safety of MVA and immunogenicity in HIV-infected and uninfected subjects. As a measure of the potential efficacy of MVA, the ability to boost the memory response in people previously vaccinated against smallpox was evaluated by the inclusion of vaccinia-experienced HIV-infected and HIV-uninfected subjects.

RESULTS

MVA was well tolerated and immunogenic in all subjects. Antibody responses were comparable between uninfected and HIV-infected populations, with only 1 significantly lower total antibody titer at 2 weeks after the second vaccination, while no significant differences were observed for neutralizing antibodies. MVA rapidly boosted the antibody responses in vaccinia-experienced subjects, supporting the efficacy of MVA against variola.

CONCLUSIONS

MVA is a promising candidate as a safer smallpox vaccine, even for immunocompromised individuals, a group for whom current smallpox vaccines have an unacceptable safety profile.

Для цитирования: Greenberg Richard N, Overton Edgar Turner, Haas David W, Frank Ian, Goldman Mitchell, von Krempelhuber Alfred, Virgin Garth, Bädeker Nicole, Vollmar Jens, Chaplin Paul. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.. The Journal of infectious diseases. 2012. DOI: 10.1093/infdis/jis753.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.